Filing Flows › Industrials › Nautilus Biotechnology (NAUT)
Nautilus Biotechnology (NAUT) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 27, 2026 · Nautilus Biotechnology (NAUT) Q3 2026 earnings results →
Nautilus Biotechnology made $234K in Q3 2026. Operating margin n/m, net loss $15.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 27, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $234K in Q3 2026, up 23% from the previous quarter.
Operating costs exceeded revenue by $15.6M, an operating margin of -6682.1%. The quarter ended with a net loss of $15.6M, wider than the previous quarter's $14.5M loss.
Operating cash flow was −$13.3M. Non-cash charges added back $200K of depreciation and $1.3M of share-based compensation. Working capital and other items added $863K. Capital expenditures of $1.4M exceeded it, leaving free cash flow of −$14.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 27, 2026 | $234K | — | n/m | −$15.6M | −$13.3M |
| Q2 2026 | 10-Q | Jul 28, 2026 | $190K | — | n/m | −$14.5M | −$13.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Nautilus Biotechnology
On June 9, 2021 (the “Closing Date”), Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp III (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “Business Combination Agreement”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (“Legacy Nautilus”).
In its own words, from its 10-K, filed Feb 26, 2026.
Nautilus Biotechnology against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NAUT Nautilus Biotechnology | Q3 2026 | $234K | — | n/m |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: Nautilus Biotechnology 10-Q on SEC EDGAR · CIK 1808805 · Laboratory Analytical Instruments
13F: who owns NAUT and who is buying
More on NAUT
History
Every quarter: Q3 2026 results · Q2 2026 results